✦ LIBER ✦

Optimizing Bone Health and Minimizing Skeletal Morbidity in Men with Prostate Cancer

✍ Scribed by McKay, Rana R.; Taplin, Mary-Ellen; Choueiri, Toni K.

Book ID: 121706666
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 631 KB
Volume: 27
Category: Article
ISSN: 0889-8588
DOI: 10.1016/j.hoc.2013.08.009

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

ZOLEDRONIC ACID REDUCES SKELETAL MORBIDI

ZOLEDRONIC ACID REDUCES SKELETAL MORBIDITY REGARDLESS OF PREVIOUS SKELETAL EVENTS IN MEN WITH PROSTATE CANCER AND BONE METASTASES

✍ F. Saad; D.M. Gleason; R. Murray; S. Tchekmedyian 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Skeletal Morbidity in Men with Prostate

Skeletal Morbidity in Men with Prostate Cancer: Quality-of-Life Considerations throughout the Continuum of Care

✍ Fred Saad; Carl Olsson; Claude C. Schulman 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 227 KB

572Long-term reduction of bone pain and

572Long-term reduction of bone pain and skeletal morbidity with zoledronic acid in patients with prostate cancer and bone metastases

✍ F. Saad; J. Eastham; J. McKieman; D. Gleason; M. Zheng 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 198 KB

Bone Health in Men Receiving Androgen De

Bone Health in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

✍ Eastham, James A. 📂 Article 📅 2007 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 266 KB

Management of Bone Loss in Men With Pros

Management of Bone Loss in Men With Prostate Cancer

✍ HIGANO, CELESTIA S. 📂 Article 📅 2003 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 91 KB

Androgen deprivation therapy increases c

Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer

✍ Christopher S. Saigal; John L. Gore; Tracey L. Krupski; Janet Hanley; Matthias S 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB

## Abstract ## BACKGROUND. The use of androgen deprivation therapy (ADT) in the treatment of men with prostate cancer has risen sharply. Although cardiovascular disease is the most common reason for death among men with prostate cancer who do not die of the disease itself, data regarding the effec